Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study
April 20, 2023 16:01 ET
|
Junshi Biosciences
Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to...
Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
April 11, 2023 23:47 ET
|
Junshi Biosciences
SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
April 11, 2023 23:34 ET
|
Junshi Biosciences
SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
March 31, 2023 04:00 ET
|
Junshi Biosciences
SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
March 28, 2023 23:39 ET
|
Junshi Biosciences
-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab -- Excellmab will be responsible for the...
Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
February 27, 2023 23:50 ET
|
Junshi Biosciences
SHANGHAI, China, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study
February 20, 2023 22:53 ET
|
Junshi Biosciences
SHANGHAI, China, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has...
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 15, 2023 09:26 ET
|
Junshi Biosciences
- Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC - SHANGHAI,...
Junshi Biosciences Announces Approval for Marketing of VV116 in China
January 30, 2023 08:24 ET
|
Junshi Biosciences
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Acceptance of NDA for VV116 in China
January 17, 2023 23:11 ET
|
Junshi Biosciences
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...